This is a first-in-human (FIH study designed to evaluate safety, tolerability, pharmacokinetic, and pharmacodynamic effects of AKB-9090 in healthy adult participants. The study consists of two stages: Stage 1, a single ascending dose (SAD) phase with five dose cohorts, and Stage 2, a multiple ascending dose (MAD) phase with three dose cohorts. Approximately 40 participants in SAD and 30 in MAD are planned to be enrolled.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of participants who will report serious Treatment emergent adverse events (TEAEs) and TEAEs
Timeframe: From First Dose to Day 7
Number of Participants with Clinically Significant Changes in Physical Examinations
Timeframe: From First Dose to Day 7
Number of Participants with Clinically Significant Changes in Vital Signs
Timeframe: From First Dose to Day 7
Number of Participants with Clinically Significant Changes in 12-lead Electrocardiogram (ECG)
Timeframe: From First Dose to Day 7
Number of Participants with Clinically Significant Changes in Chemistry parameters
Timeframe: From First Dose to Day 7
Number of Participants with Clinically Significant Changes in Hematology Parameters
Timeframe: from first dose to Day 7
Number of Participants with Clinically Significant Changes in Lipid Parameters
Timeframe: From First Dose to Day 7
Number of Participants with Clinically Significant Changes in Coagulation Parameters
Timeframe: From First Dose to Day 7
Number of Participants with Clinically Significant Changes in Urinalysis Parameters
Timeframe: From First Dose to Day 7